Pharma BD Deal Intelligence
Ipsen obtained exclusive licensing rights to commercialize and develop cabozantinib outside the United States, Canada, and Japan. The deal included a $200 million upfront payment plus up to $545 million in commercial milestones and tiered royalties up to 26%.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Exelixis Inc. (this deal) | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2016 deals · Ipsen S.A. deals · Oncology deals